At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
In Brief
A Phase 4 clinical trial evaluating Superparamagnetic Iron Oxide Magnetic Resonance Imaging for Pancreatic Cancer. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The purpose of this research study is to see if a specific kind of MRI, called Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI), which uses an FDA-approved therapeutic agent(Feraheme) to see if it is able to identify small and otherwise undetectable lymph node metastases in people who have pancreatic cancer and are scheduled for surgical resection.
Study Details
Timeline
Interventions
Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol